Exchange Traded Concepts LLC Sells 8,574 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Exchange Traded Concepts LLC decreased its position in shares of Replimune Group, Inc. (NASDAQ:REPL) by 34.9% during the third quarter, according to its most recent filing with the SEC. The firm owned 16,010 shares of the company’s stock after selling 8,574 shares during the period. Exchange Traded Concepts LLC’s holdings in Replimune Group were worth $175,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in REPL. Quest Partners LLC increased its holdings in shares of Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after acquiring an additional 3,150 shares in the last quarter. Algert Global LLC grew its position in Replimune Group by 5.4% during the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock valued at $756,000 after purchasing an additional 4,340 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after purchasing an additional 4,946 shares in the last quarter. Los Angeles Capital Management LLC increased its stake in Replimune Group by 8.1% during the 2nd quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock valued at $646,000 after purchasing an additional 5,410 shares in the last quarter. Finally, Rhumbline Advisers raised its holdings in Replimune Group by 7.2% in the second quarter. Rhumbline Advisers now owns 84,923 shares of the company’s stock worth $764,000 after buying an additional 5,732 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Emily Luisa Hill sold 8,938 shares of Replimune Group stock in a transaction on Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the sale, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 20.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms have recently commented on REPL. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Roth Mkm assumed coverage on Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price on the stock. JPMorgan Chase & Co. lifted their target price on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Replimune Group in a report on Monday, September 16th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $16.80.

Replimune Group Stock Down 1.6 %

REPL opened at $11.35 on Tuesday. The company has a market capitalization of $697.06 million, a PE ratio of -3.50 and a beta of 1.21. The firm has a 50-day simple moving average of $10.81 and a two-hundred day simple moving average of $8.89. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16. Replimune Group, Inc. has a 52 week low of $4.92 and a 52 week high of $15.18.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.88) by $0.10. Analysts forecast that Replimune Group, Inc. will post -3.11 earnings per share for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.